Research programme: fibroblast growth factor receptor inhibitors - Cogent Biosciences
Alternative Names: FGFR2 inhibitors - Cogent BiosciencesLatest Information Update: 08 Aug 2024
At a glance
- Originator Cogent Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Aug 2024 Cogent Biosciences plans a phase I trial for Cancer in the second half of 2024.
- 02 Nov 2023 Pharmacodynamics data from a preclinical studies in Cancer released by Cogent Biosciences
- 17 Apr 2023 Initial pharmacodynamics data from a preclinical trial in Cancer released by Cogent Biosciences